| Business Summary | | Delcath
Systems,
Inc.
has
developed
a
system,
the
Delcath
system,
to
isolate
the
liver
from
the
general
circulatory
system
and
to
administer
chemotherapy
and
other
therapeutic
agents
directly
to
the
liver.
The
Delcath
system
is
designed
to
address
the
critical
shortcomings
of
conventional
intravenous
chemotherapy
delivery.
The
Delcath
system
is
not
currently
approved
for
marketing
by
the
United
States
Food
and
Drug
Administration
(FDA),
and
it
cannot
be
marketed
in
the
United
States
without
FDA
pre-marketing
approval.
The
Company
plans
to
conduct
Phase
III
clinical
trials
designed
to
secure
marketing
approval
for
the
system
in
the
United
States
and
possibly
in
foreign
markets. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Delcath
Systems,
Inc.
has
developed
a
drug-delivery
system,
currently
awaiting
FDA
approval,
to
isolate
the
liver
from
the
general
circulatory
system
and
to
administer
chemotherapy
and
other
therapeutic
agents
directly
to
the
liver.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
totaled
$904
thousand,
up
from
$392
thousand.
Higher
loss
reflects
higher
legal
consulting
and
accounting
fees
and
increased
compensation
costs. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Samuel Herschkowitz, M.D., 51 Chairman,
CTO | -- | M. Koly, 60 Pres,
CEO, Treasurer, Director | $98K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|